Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation
09 déc. 2024 08h00 HE
|
Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscl
Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market
06 déc. 2024 07h30 HE
|
Elevai Labs Inc.
Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market
Elevai Labs Inc. Announces Record-Breaking Sales Month in 2024 for Elevai Skincare Division
04 déc. 2024 08h00 HE
|
Elevai Labs Inc.
Elevai Labs Inc. Announces Record-Breaking Sales Month in 2024 for Elevai Skincare Division
Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance
22 nov. 2024 18h23 HE
|
Elevai Labs Inc.
Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance
Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess
22 nov. 2024 17h00 HE
|
Elevai Labs Inc.
Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess
CORRECTION - Elevai Labs Inc.
14 nov. 2024 14h35 HE
|
Elevai Labs Inc.
/CORRECTION/ Elevai Labs Inc. Reports Financial Results for the Third Fiscal Quarter of 2024 and Provides Business Update
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
14 nov. 2024 09h08 HE
|
Elevai Labs Inc.
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange
04 nov. 2024 17h45 HE
|
Elevai Labs Inc.
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity
22 oct. 2024 09h54 HE
|
Elevai Labs Inc.
Elevai Biosciences Engages Leading CRO to Support Regulatory Planning Efforts and Pre-IND Meeting with the FDA for EL-22 For The Treatment of Obesity
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity
21 oct. 2024 07h30 HE
|
Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Bl